Related Experiment Video
Updated: Mar 13, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Rituximab in autoimmune diseases.
1Department of Immunology, Canberra Hospital.
Rituximab, a B-cell depleting monoclonal antibody, shows efficacy in treating rheumatoid arthritis and vasculitis. Further research is needed for other autoimmune conditions, with careful patient screening essential before treatment.
Area of Science:
- Immunology
- Rheumatology
- Oncology
Background:
- Rituximab, a monoclonal antibody, targets B cells.
- Initially for lymphoma, its use expanded to autoimmune diseases.
- Demonstrated efficacy in rheumatoid arthritis and ANCA-associated vasculitis.
Approach:
- Review of rituximab's application in autoimmune conditions.
- Analysis of evidence from randomized controlled trials.
- Consideration of baseline patient assessments and contraindications.
Key Points:
- Effective in rheumatoid arthritis and granulomatosis with polyangiitis.
- Limited evidence for efficacy in many other autoimmune diseases.
- Pre-treatment screening of immunoglobulins, immunizations, and infections is crucial.
Conclusions:
- Rituximab is a valuable therapeutic option for specific autoimmune diseases.
- Careful patient selection and monitoring are necessary.
- Further investigation is warranted for broader autoimmune applications.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease III: Medical Management

